JPRN-UMIN000001595已完成2 期
Randomized phase II study comparing Gemcitabine versus TS-1 for advanced bile duct cancer - Randomized phase II study comparing GEM versus TS-1 for advanced bile duct cancer
Osaka International Cancer Institute Department of Hepatobiliary and pancreatic Oncology0 个研究点目标入组 110 人开始时间: 2008年12月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.lung fibrosis or intestinal pneumonia 2.Watery diarrhea 3.Severe infection 4.Severe complication (heart failure, renal failure, hepatic insufficiency,hemorrhagic peptic ulcer, intestines paralysis,ileus or uncontrolled diabetes etc) 5.Medical history of serious allergy reactions to any drug 6.Massive pleural or abdominal effusion 7.Metastasis to central nervous system 8.Active synchronous or metachronous malignancy other than carcinoma in situ 9.Regular use of frucitocin, fenitoin or warfarin 10.Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy 11.Severe mental illness 12.Patients who are judged inappropriate for the entry into the study by the investigater
研究者
相似试验
进行中（未招募）
1 期
Full-dose single-agent chemotherapy (gemcitabine) or reduced-dose combination chemotherapy as first palliative treatment for fragile patients with advanced pancreatic cancer.Pancreatic CancerEUCTR2021-005067-52-DKAalborg University Hospital, Department of Oncology100
已完成
2 期
Randomized phase II study comparing Gemcitabine chemoradiotherapy with Gemcitabine chemotherapy for unresectable locally advanced pancreatic cancer.nresectable locally advanced pancreatic cancer.JPRN-UMIN000012253Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology110
已完成
2 期
A randomized phase II study of Gemcitabine or Gemcitabine + S-1 as adjuvant chemotherapy for resected biliary tract cancerBiliary tract cancer (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder carcinoma)JPRN-UMIN000007244Adjuvant Therapy for BTC Research Group130
已完成
2 期
Randomized phase II study comparing Gemcitabine/TS-1 combination chemoradiotherapy with Gemcitabine/TS-1 combination chemotherapy for unresectable locally advanced pancreatic cancer.nresectable locally advanced pancreatic cancer.JPRN-UMIN000001990Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology110
进行中（未招募）
不适用
Randomised phase II/III study comparing gemcitabine followed by gemcitabine plus concomitant radiation (50.4 Gy) versus gemcitabine alone after curative pancreaticoduodenectomy for pancreatic head cancerEUCTR2005-000933-39-DEEuropean Organisation for Research and Treatment of Cancer538